Dr. Martens Future Growth
Future criteria checks 4/6
Dr. Martens is forecast to grow earnings and revenue by 40.5% and 4.9% per annum respectively. EPS is expected to grow by 40.7% per annum. Return on equity is forecast to be 15% in 3 years.
Key information
40.5%
Earnings growth rate
40.7%
EPS growth rate
| Luxury earnings growth | 10.3% |
| Revenue growth rate | 4.9% |
| Future return on equity | 15.0% |
| Analyst coverage | Good |
| Last updated | 16 Dec 2024 |
Recent future growth updates
Recent updates
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%
Dec 06
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year
Dec 01Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet
Sep 21Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?
Aug 20Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger
Jul 20There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings
Jun 19Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%
May 21The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Mar 27Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Mar 06Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Feb 08Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
Jan 21Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Jan 03Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dec 13Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation
Oct 12Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Sep 13Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)
Jul 12A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Jun 02Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency
Feb 25Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?
Dec 17The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Oct 02Dr. Martens (LON:DOCS) Knows How To Allocate Capital Effectively
Jul 04Why Investors Shouldn't Be Surprised By Dr. Martens plc's (LON:DOCS) 26% Share Price Surge
Jun 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 924 | 74 | 92 | 169 | 6 |
| 3/31/2026 | 867 | 56 | 77 | 155 | 7 |
| 3/31/2025 | 821 | 28 | 71 | 113 | 6 |
| 9/30/2024 | 806 | 29 | 204 | 227 | N/A |
| 6/30/2024 | 842 | 49 | 172 | 197 | N/A |
| 3/31/2024 | 877 | 69 | 140 | 168 | N/A |
| 12/31/2023 | 927 | 86 | 82 | 120 | N/A |
| 9/30/2023 | 978 | 103 | 24 | 72 | N/A |
| 6/30/2023 | 989 | 116 | 22 | 72 | N/A |
| 3/31/2023 | 1,000 | 129 | 21 | 73 | N/A |
| 12/31/2022 | 979 | 153 | 62 | 105 | N/A |
| 9/30/2022 | 957 | 177 | 104 | 138 | N/A |
| 6/30/2022 | 933 | 179 | 132 | 161 | N/A |
| 3/31/2022 | 908 | 181 | 159 | 184 | N/A |
| 12/31/2021 | 867 | 118 | 129 | 151 | N/A |
| 9/30/2021 | 825 | 54 | 98 | 117 | N/A |
| 6/30/2021 | 799 | 44 | 120 | 138 | N/A |
| 3/31/2021 | 773 | 35 | 142 | 159 | N/A |
| 12/31/2020 | 747 | 61 | 156 | 175 | N/A |
| 9/30/2020 | 722 | 87 | 169 | 190 | N/A |
| 6/30/2020 | 697 | 81 | 134 | 156 | N/A |
| 3/31/2020 | 672 | 75 | 100 | 121 | N/A |
| 3/31/2019 | 454 | 17 | 39 | 56 | N/A |
| 3/31/2018 | 349 | -6 | N/A | 46 | N/A |
| 3/31/2017 | 291 | -11 | N/A | 34 | N/A |
| 3/31/2016 | 232 | -12 | N/A | 26 | N/A |
| 3/31/2015 | 235 | 0 | N/A | 20 | N/A |
| 3/31/2014 | 164 | -32 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DOCS's forecast earnings growth (40.5% per year) is above the savings rate (2.1%).
Earnings vs Market: DOCS's earnings (40.5% per year) are forecast to grow faster than the UK market (14.9% per year).
High Growth Earnings: DOCS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DOCS's revenue (4.9% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: DOCS's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DOCS's Return on Equity is forecast to be low in 3 years time (15%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 03:13 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Martens plc is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Taylor | Barclays |
| David Roux | BofA Global Research |
| Louise Singlehurst | Goldman Sachs |